Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.57M | 3.26M | 4.12M | 7.62M | 3.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.55M | 5.87M | 7.14M | 10.37M | 5.66M |
| Operating Income | -5.55M | -5.87M | -7.14M | -10.37M | -5.66M |
| Income Before Tax | -6.04M | -5.77M | -5.84M | -9.33M | -4.82M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.04M | -5.77M | -5.84M | -9.33M | -4.82M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.04M | -5.77M | -5.84M | -9.33M | -4.82M |
| EBIT | -5.55M | -5.87M | -7.14M | -10.37M | -5.66M |
| EBITDA | -5.54M | -5.87M | -7.11M | -10.34M | -5.61M |
| EPS Basic | -0.07 | -0.07 | -0.07 | -0.13 | -0.07 |
| Normalized Basic EPS | -0.05 | -0.04 | -0.05 | -0.08 | -0.04 |
| EPS Diluted | -0.07 | -0.07 | -0.07 | -0.13 | -0.07 |
| Normalized Diluted EPS | -0.05 | -0.04 | -0.05 | -0.08 | -0.04 |
| Average Basic Shares Outstanding | 82.65M | 82.61M | 80.41M | 69.84M | 68.75M |
| Average Diluted Shares Outstanding | 82.65M | 82.61M | 80.41M | 69.84M | 68.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |